These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Relationship between primary and metastatic testicular germ cell tumors: a clinicopathologic analysis of 100 cases. Tarrant WP; Czerniak BA; Guo CC Hum Pathol; 2013 Oct; 44(10):2220-6. PubMed ID: 23856516 [TBL] [Abstract][Full Text] [Related]
7. Controversies in the management of stage 1 non-seminomatous germ cell tumors. Coleman S; Stephenson A Curr Urol Rep; 2013 Oct; 14(5):506-10. PubMed ID: 23901036 [TBL] [Abstract][Full Text] [Related]
8. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer. Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567 [TBL] [Abstract][Full Text] [Related]
9. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease? Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432 [TBL] [Abstract][Full Text] [Related]
12. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in patients with stage I non-seminomatous germ cell cancer. Lv ZJ; Wu S; Dong P; Yao K; He YY; Gui YT; Zhou FJ; Liu ZW; Cai ZM Asian J Androl; 2013 Jul; 15(4):558-63. PubMed ID: 23685909 [TBL] [Abstract][Full Text] [Related]
14. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection. Baessler B; Nestler T; Pinto Dos Santos D; Paffenholz P; Zeuch V; Pfister D; Maintz D; Heidenreich A Eur Radiol; 2020 Apr; 30(4):2334-2345. PubMed ID: 31828413 [TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients. Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130 [TBL] [Abstract][Full Text] [Related]
16. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Mano R; Di Natale R; Sheinfeld J Urol Oncol; 2019 Mar; 37(3):209-218. PubMed ID: 30446455 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor. Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699 [TBL] [Abstract][Full Text] [Related]